II. Mechanism
III. Indications
- Severe familial Hypercholesterolemia (e.g. LDL Cholesterol >190 mg/dl)
IV. Dosing: Adults
- May be used in age 13 to 17 years (but not FDA approved in this age group)
- Store in refrigerator at 36 to 46 degrees
- May also store in original carton up to 30 days at room Temperature <77 F
- Administer subcutaneously in the Abdomen, back of the upper arm or the thigh
- Administration of full dose may require 15 to 20 seconds
- Evolocumab
- Every 2 weeks (Sureclick syringe): 140 mg SC
- Monthly (Pushtronex infusion device): 420 mg SC
V. Efficacy
- See PCSK9 Inhibitor
- Lower LDL Cholesterol 42 to 65% with or without a Statin
- Evolocumab added to Statin for 2 years prevents one more CV event per 74 treated ($2,000,000 per CV event prevented)
- Reanalysis of FOURIER Trial data demonstrated a slightly higher cardiovascular mortality with Repatha
VI. Disadvantages
- See PCSK9 Inhibitor
- Costs $450 per 2 weeks (>$10,000 per year) in 2022
VII. Safety
- Unknown safety in pregnancy
- Unknown safety in Lactation
VIII. Reources
IX. References
- (2015) Presc Lett 22(9): 50-1
- (2022) Non-StatinLipid Lowering Agents, Presc Lett, #380202
- (2022) Med Lett Drug Ther 64(1659): 145-52
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
- Robinson (2015) N Engl J Med 372(16):1489-99 +PMID:25773378 [PubMed]
- Stroes (2014) J Am Coll Cardiol 63(23):2541-8 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
| repatha (on 7/1/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| REPATHA 140 MG/ML SURECLICK | $251.85 per ml | |
| REPATHA 140 MG/ML SYRINGE | $251.22 per ml | |
| REPATHA 420 MG/3.5 ML PUSHTRONX | $156.51 per ml | |